Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 26, Issue 21, 2008, Pages 3645-3646

  Pitini, Vincenzo ^a   Arrigo, Carmela ^a   Altavilla, Giuseppe ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANAMNESIS; ARTICLE; BONE MARROW BIOPSY; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DNA SEQUENCE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LUNG NON SMALL CELL CANCER; MALE; NEEDLE BIOPSY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; APOPTOSIS; BIOSYNTHESIS; DRUG EFFECT; GENETICS; LUNG TUMOR; MIDDLE AGED; MULTIPLE CANCER; MUTATION; SMOKING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LEUKEMIA, MYELOID, ACUTE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 49049087562     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.0357     Document Type: Article

References (8)

1. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501, 1992
2. Sequist LV, Bell DW, Lynch TJ, et al: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587-595, 2007
3. Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 23:2556-2568, 2005
4. Rosell R, Taron M, Sanchez JJ, et al: Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncol 3:277-283, 2007
5. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007
6. Stegmaier K, Corsello SM, Ross KN, et al: Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106:2841-2848, 2005
7. Boehrer S, Adès L, Braun T, et al: Erlotinib exhibits antineoplastic off-target effects in AML and MDS: A preclinical study. Blood 111:2170-2180, 2008
8. Chan G, Pilichowska M: Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non-small-cell lung cancer. Blood 110:1079-1080, 2007